Should Investors Worry About the Federal Investigation of Cassava?

Cassava Sciences (NASDAQ: SAVA) has been embroiled in a controversy for several months related to allegations that it falsified data for its experimental Alzheimer's disease drug simufilam. Last month, the company revealed that it's the subject of a federal investigation. In this Motley Fool Live video recorded on Nov. 16, Fool contributors Keith Speights and Brian Orelli discuss whether investors should worry about this development.

Continue reading

Source Fool.com